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MikroRNA:t ovat lyhyitä RNA-molekyylejä, jotka säätelevät geeniekspressiota
sitoutumalla lähetti-RNA-molekyyleihin estäen siten niiden translaation pro-
teiiniksi. Aiemmat tutkimukset ovat osoittaneet, että mikroRNA:t osallistuvat
monipuolisesti solujen toiminnan säätelyyn, kuten erilaistumiseen ja apoptoosiin,
ja ovat osallisena monien tautien, kuten syövän synnyssä.
MikroRNA:n säätelemien kohdegeenien tunnistaminen on olennainen askel
mikroRNA:n toiminnan ymmärtämisessä. Kohdegeenien ennustamiseen on
kehitetty lukuisia laskennallisia menetelmiä. Varhaiset menetelmät perustui-
vat RNA-sekvenssien vertailuun. Uudemmat työkalut yhdistävät geeni- ja
mikroRNA-ekspressiodataa kohdegeenien tunnistamiseksi. Proteiini-, geeni-
ja mikroRNA-ekspressiota yhdistäviä kohdegeenien tunnistamiseen tähtääviä
tutkimuksia on julkaistu toistaiseksi suhteellisen vähän.
Rintasyöpä on naisten yleisin syöpä ja merkittävä sairastavuuden ja kuolleisuuden
aiheuttaja maailmanlaajuisesti. Geeniekspressiodatan analysointi on lisännyt tietoa
rintasyövän synnystä, ja geeniekspressioon perustuen on kyetty tunnistamaan
rintasyövän alatyyppejä, jotka korreloivat syövän ennusteeseen. MikroRNA:n on
todettu olevan osatekijä rintasyövän synnyssä.
Tässä diplomityössä sovellettiin äskettäin julkaistua bayesilaista muuttujavalinta-
menetelmää mikroRNA-molekyylien kohdegeenien ennustamiseen rintasyövässä.
Tähän tarkoitukseen käytettiin proteiini-, geeni- ja mikroRNA- ekspressiodataa.
Tulokset osoittivat, että menetelmä soveltuu kohdegeenien ennustamiseen. Työssä
esitetään vaihtoehtoja mallin jatkokehittämiseksi.
Avainsanat: bayesilainen analyysi, geeniekspressio, kohdegeenien ennustaminen,
mikroRNA, mikrosiru, rintasyöpä
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Symbols and abbreviations
Symbols
β Regression coefficients for explanatory variables
‖β‖1 The 1-norm of β
Eθ(x) Expectation of random variable x over parameters θ
n Number of observations
N(µ, σ2) Multivariate normal distribution with mean µ and variance σ2
pn Number of (assumed) true explanatory variables in variable seĺection
p(y) Probability density of x
p(y, θ) Joint probability of y and θ
p(y|θ) Conditional probability of y given θ
θ Parameters of a probability model
x Explanatory variable (or microRNA expression vector)
X Matrix of explanatory variables (or microRNA expression vectors)
y Outcome variable (or protein expression vector)
y ∼ N(.) Random variable y has probability distribution N(.)
y ∝ x y is proportional to x, up to a constant factor
z mRNA expression vector
Abbreviations
bp Base pairs (as a measure of double-stranded sequence length)
HMM Hidden Markov model
lasso Least absolute shrinkage and selection operator
LPD log predictive density
MCMC Markov chain Monte Carlo
miRNA MicroRNA
MLPD Mean log predictive density
MLR Multivariate linear regression
mRNA Messenger RNA
NGS Next-generation sequencing
nt Nucleotides (as a measure of sequence length)
PCR Polymerase chain reaction
PPVS Projection predictive variable selection
qPCR Quantitative PCR
RISC RNA-induced silencing complex
RNAi RNA interference
RPPA Reverse-phase protein array
SVM Support vector machine
UTR Untranslated region at the beginning (5’) or end (3’) of a
messenger RNA
WHO World Health Organization
1 Introduction
MicroRNAs (miRNAs) are short single-stranded RNA-molecules, that act in post-
transcriptional regulation of gene expression [7]. They have been found in a wide
variety of animals and plants, and also in viruses. MicroRNAs are highly conserved
in evolution and function in diverse developmental, physiological and pathological
processes. miRNAs have also been indicated in the formation of numerous diseases,
including several types of cancer [12]. Therefore, the study of microRNAs and their
function in cancer can offer insights into tumorigenesis and cancer progression as
well as potential new biomarkers and treatments.
Identifying the target genes regulated by microRNAs is key to understanding their
function, both in cellular physiology and pathology. Experimental laboratory studies
to identify miRNA targets are both laborious and costly. In fact, finding all miRNA
targets by experimental studies alone is unfeasible, considering that any gene is
potentially targeted by any miRNA, giving rise to tens of millions of potential
interactions.
A plethora of methods for computational identification of microRNA target genes
have, thus, been developed [77]. Early methods were based on sequence similarity
of the microRNA and messenger RNA (mRNA) of putative target genes. More
recent methods compare the expression profiles of miRNAs and mRNAs in cell
cultures or tissue samples to elucidate interactions transpiring in cells. Most of these
expression-based methods rely on variations of correlation or multivariate linear
regression, though more complex models have also been proposed. The combinatorial
nature of miRNA action, however, makes expression-based strategies difficult, as
most transcripts are regulated by several miRNAs simultaneously, the contribution
of individual miRNAs may be small, and most miRNAs target a large number of
transcripts [6].
Cancer is a genetic disease caused by mutations in the genome of tumor cells [46].
Some of these mutations can be inherited, while some arise during the life-time of
an individual. To understand how cancer develops, it is of paramount importance
to identify genes which contribute to the tumorigenesis. It is also essential to
determine genes, and other factors, that influence cancer aggressiveness as well as
treatment sensitivity and resistance so that better and more targeted treatments can
be developed.
Breast cancer is the most common of female cancers and causes remarkable morbidity
and mortality word-wide. Annually more than 1.5 million women develop breast
cancer [34]. Thus, breast cancer constitutes a major global health problem. Previous
studies comparing the expression profiles of normal breast tissue and breast cancer
tissue have revealed that expression signatures classify breast cancers into distinct
subtypes, which are associated with prognosis [94]. Recent studies have suggested
that microRNAs can explain some of the heterogeneity and pathology of breast
cancer and show promise as prognostic markers [106].
2The aim of this thesis was to apply a recently proposed Bayesian variable selection
method to microRNA target discovery in breast cancer. Variable selection was
applied in the context of Bayesian regression, incorporating protein, mRNA and
miRNA expression profiles, to elucidate which microRNAs are relevant in regulating
protein expression levels. The prediction results were compared with lasso regression,
a popular method for target prediction, and with experimentally validated microRNA
targets.
32 Gene expression
Genetic information is encoded in deoxyribonucleic acid (DNA). A gene is a section
of DNA that serves as a template for a functional ribonucleic acid (RNA) molecule.
Gene expression refers to this process of synthesizing a functional end-product from
the information contained in gene. DNA and gene expression serve as the basis of
all currently known life [97].
Most of gene expression is dedicated to production of proteins. The Central Dogma of
Molecular Biology, postulated by Francis Crick in 1970, describes the general schema
of how genetic information flows from genes to proteins; DNA is first transcribed
into messenger RNA (mRNA), which is then translated into polypeptides, which
ultimately form proteins [20] (illustrated in Figure 1). The flow is not strictly one-
directional, though, as reverse transcriptases, a family of enzymes, can synthesize
DNA from an RNA template.
DNA
TRANSCRIPTIONRNA polymerase
mRNA
TRANSLATION
Protein
Ribosome
Figure 1: The Central Dogma of Molecular Biology, as postulated by Crick [20]. Most genetic
information flows from DNA to RNA to protein.
All genes are transcribed to RNA, but all do not encode proteins. The human
genome1 has been suggested to contain approximately 20 500 protein-coding genes,
which encompass only around 1.5% of the whole genetic sequence [19]. The vast
majority of the human genome was, thus, previously thought to be without function
and referred to as "junk DNA". More recently, however, it has become evident that
human DNA is pervasively transcribed, the majority of it appears functional, and
many coding and non-coding regions overlap in the DNA [97].
Non-coding genes give rise to non-coding RNA (ncRNA), a class of RNA molecules
that both participate in and regulate the expression of other genes. Examples of
known ncRNAs and their functions are presented in Table 1. Nevertheless, the
1The genome refers to the whole genetic material of an organism or an individual.
4Table 1: Examples of known major classes of human non-coding RNA and their general
functions. This table is not exhaustive and several additional classes have been discovered.
Table adapted from [97].
Size: approximate sequence lengths of each class in number of nucleotides. Abbrev.:
abbreviations commonly used.
RNA class Abbrev. Size (nt) Function
Ribosomal RNA rRNA 120–5,000 Components of ribosomes (which perform
translation)
Transfer RNA tRNA 70–80 Transporting peptides and decoding
mRNA sequence into peptides
Small nuclear RNA snRNA 60–360 Intron splicing; regulation of transcription,
chromosomal replication and cell cycle etc.
MicroRNA miRNA 21–24 Post-transcriptional gene regulation
Small interfering RNA siRNA 21–22 Post-transcriptional regulation
Long non-coding RNA lncRNA > 1,000 Gene regulation at several stages
function and significance (if any) of many transcribed and non-coding regions of the
genome still remains poorly understood.
2.1 Regulation of gene expression
The proper regulation of gene expression is paramount for cells to respond to external
signals, changes in their environment, and to go through different developmental
stages. Gene expression is, thus, under complex control mechanisms, which result in
tissue and cell-specific expression. This regulation occurs on several stages including
transcriptional, post-transcriptional, translational and post-translational regulation
[97].
The first step of this regulation is control of transcription. To be transcribed, genes
need active initiation of transcription, which occurs in the promotor regions. While the
actual transcription is performed by RNA polymerases, many different transcription
factors and regulatory proteins participate in its regulation. Transcription is possible
only when the chromatin structure of the transcribed genetic region is opened from
its tight package around histone proteins, which is controlled by additional factors
such as histone acetylation.
The produced mRNA undergoes post-transcriptional modifications, such as capping,
polyadenylation and splicing of introns, which all are essential for further translation
of the mRNA to protein [97]. All these steps must maintain a certain level of fidelity,
as even slight structural changes can render both mRNA and protein to degradation
and. The main post-transcriptional control mechanism seems to be RNA interference
(RNAi). It causes suppression of gene expression through mRNA degradation and
inhibition of translation. MicroRNAs (miRNAs) and small interfering RNAs (siRNAs)
are central components of the RNAi pathway; they act as target mRNA recognizing
templates [24]. MicroRNAs, which are the focus of this study, are discussed in more
detail in the next section.
5The translation of mRNA to protein can also be directly regulated, but this seems
less prevalent than control of previous phases. Post-translationally, proteins can be
modified and degraded to affect their function and cellular expression levels [97].
2.2 Quantification of gene expression
The quantitative measurement of gene expression can be done on either the level of
messenger RNA molecules or protein molecules. Although proteins are the eventual ef-
fector molecules – at least for protein-coding genes – gene expression is usually thought
to be synonymous with mRNA expression. mRNA abundances are significantly easier
to measure than protein abundances, due to the chemistry of hybridization and the
relative ease of replicating DNA and RNA sequences by exploiting cellular machinery
evolved for this purpose.
Quantitative PCR (qPCR) is a DNA/RNA measurement method based on the
polymerase chain reaction (PCR). It measures the number of specific DNA or
RNA molecules present in a sample during each cycle of the PCR amplification
process. These are then extrapolated to obtain gene expression values. qPCR has
been considered a golden standard for measuring gene expression and is widely used
in research, but also in clinical diagnostics. It is often the method of choice for
measuring a moderate number of genes, but does not scale well into large numbers
of genes [107].
Gene expression microarrays are based on probes printed on a solid surface, where
each probe has been designed to have complementary sequence corresponding to a
target mRNA. The amount of mRNA hybridized to the probes provides an estimate
of gene expression. The advantage of microarrays is that they allow massively parallel
analysis on the whole genome level. They are also relatively inexpensive and easy
to use, making them a ubiquitous tool for expression measurements. Detection of
expression levels is based on fluorescence and optical sensors and is subject to noise
due to imperfect probe design and technical limitations. As microarray data are
inherently noisy, proper normalization methods have been shown to be important.
Probe designs can also become obsolete as reference genomes are updated and,
therefore, reassessment of the true targets of probes is advisable [2].
More recently next-generation sequencing methods have been applied to gene ex-
pression profiling. These are not dependent on previous reference sequences, but are
relatively expensive and laborious compared to microarrays.
Protein expression can be measured using several different methods. Perhaps most
widely used are different variations of mass spectrometry (MS). Application of mass
spectrometry is limited by its resource-intensiveness and poor scalability, however.
Reverse-phase protein arrays (RPPA) are a platform comparable to microarrays,
where samples are fixed to a solid surface and then probed with antibodies binding
to specific proteins [13]. This allows measuring a single protein for several samples
simultaneously. RPPAs are inexpensive, allow reasonably large-scale analyses, and
6analysis of RPPA data is similar to gene expression arrays, making them an attractive
choice for studies using multiomics data [71].
The general assumption has been that mRNA expression is representative of gene
expression and that changes in mRNA abundances also reflect changes in protein
abundances. This assumption has recently been challenged by experiments indicating
that correlations between the expression of mRNA and corresponding protein are low,
with mRNA expression explaining around 40% of variation in protein expression [112].
Payne recently concluded that "proteome and transcriptome abundances are not
sufficiently correlated to act as proxies for each other" and that most of this difference
is likely caused by biological regulation and not by measurement technology [82].
Therefore, it is beneficial, even necessary, to integrate measurements from different
stages of gene expression – for example mRNA, microRNA and protein abundances –
to gain better and novel insight into biological processes.
73 MicroRNAs
MicroRNAs (miRNAs) are a class of endogenous (i.e. synthesized within the cell)
non-coding small RNA molecules that function as post-transcriptional regulators of
gene expression [3]. In their functional, mature form miRNAs are single stranded
and approximately 22 nucleotides long. MicroRNAs are not translated into protein.
Instead, they have an important role in regulation of gene expression in a wide range
of physiological, developmental and pathological processes [8]. MicroRNAs assert
their regulatory function by destabilization and degradation of target messenger
RNA (mRNA) molecules and inhibition of mRNA translation [33].
3.1 Discovery of microRNAs
The first known microRNA, lin-4, was discovered in 1993 by two research groups
studying the larval development of the nematode Caenorhabditis elegans. The
researchers noted that lin-4 does not encode a protein, but instead produces a
pair of small RNAs, the longer of which was proposed to be a precursor to the
shorter one [65]. The RNAs encoded by lin-4 were noted to have conserved antisense
complementarity in several sites of an untranslated region of the lin-14 mRNA, and
these sites were found to be necessary for the normal repression of lin-14 expression
by lin-4 [65, 115].
Let-7, the second microRNA to be discovered, was also first found in C. elegans,
however, homologues of let-7 were later found in several other species [81]. Soon after,
numerous microRNA genes were found across a variety of species, and a registry was
set up to serve as a comprehensive knowledge base of published microRNAs and
as an independent authority on microRNA nomenclature [42]. This registry later
became miRBase, the de facto reference database of known microRNAs, and now
provides sequence data, annotations, as well as links to databases of predicted and
validated target genes for miRNAs [59].
3.2 MicroRNA genomics
The number of known small RNAs has since vastly expanded and microRNAs have
been found in more than 200 organisms, including all studied animals, plants [54]
and viruses [43]. The number of records in miRBase has risen exponentially to 35,828
mature miRNAs for 223 species (including 2,588 human miRNAs) in the most recent
version (v21, released June 2014 [75]). This illustrates the large number of novel
microRNA molecules discovered recently, which has been mainly due to increasing
efforts in and availability of sequencing. miRBase lists 2,588 known human miRNAs
at the time of writing this thesis.
MicroRNAs are highly conserved in evolution [7]. For instance, approximately 55% of
C. elegans miRNAs have homologues in humans [52]. Interestingly, the appearance
8of multi-cellular organisms appears to co-occur with the appearance of the microRNA
machinery. Organism complexity and speciation also seem to correlate with miRNA
complexity, together suggesting that microRNAs have had a crucial role in the
development of complex organisms [63].
MicroRNAs are found in varying genomic contexts in the DNA. Approximately 50%
of mammalian miRNAs are located in close proximity to other miRNAs and form
polycistronic miRNA clusters that are transcribed simultaneously. Some miRNAs
reside in the genome as dedicated miRNA genes, with their own promotor regions.
[57] miRNAs and miRNA clusters can be situated in exons or introns of non-coding
genes and some are found in introns of protein-coding genes [24].
MicroRNAs are expressed in all tissues, however, different tissues have differing
miRNA expression profiles [61]. Many microRNAs also have differing expression in
different developmental stages of an organism, often functioning as molecular switches
to move between stages. For instance, let-7 functions to control the transition from
late larval to adult stage in C. elegans [7].
3.3 MicroRNA biogenesis
The canonical pathway of microRNA biogenesis is illustrated in Figure 3 and is
presented here as reviewed by Bartel [7], Melo and Esteller [73], Ha and Kim [45],
and many others.
Most microRNAs are transcribed from genomic DNA by RNA polymerase II to form
a long primary microRNA (pri-miRNA) molecule [67]. The pri-miRNA molecule
contains a hairpin structure, with a 33-bp double-helix stem and a terminal loop,
and flanking single-strand sequences, which are several hundreds or thousands of
nucleotides long [56].
The pri-miRNA is cut by the ribonuclease Drosha to form a pre-microRNA (pre-
miRNA), which consists of the hairpin and is approximately 70 nt long [66]. Examples
of typical pre-miRNA structure are shown in Figure 2. Drosha is aided by its cofactor
DGRC8 and they form a complex known as the Microprocessor [41]. The hairpin is
then exported from the nucleus to the cytoplasm by Exportin 5 (XPO5), a member
of the nuclear transport receptor family [70].
In the cytoplasm, the ribonuclease Dicer cleaves out the loop of the hairpin to form a
22-nt-long double-stranded miRNA:miRNA* duplex corresponding to the stem of the
hairpin [9]. Dicer associates with a cofactor, in humans TRBP (Tar RNA-binding
protein), which is not required for effective dicing of the pre-miRNA, but acts to
physically bridge the Dicer to an Argonaute protein [16].
The duplex is then bound by the Argonaute protein, in mammals one of Ago1 through
Ago4, forming what is called the RNA-induced silencing complex (RISC). The RISC
is a protein complex containing Dicer, TRBP and Ago [40]. Ago, aided by Dicer and
TRBP, unwinds the strands of the duplex and retains one of them. The retained
9Figure 2: Hairpin structure of three pre-miRNAs from C. elegans. Red and gray colors indicate
the sequences of mature miRNAs. Reprinted with permission from [7].
strand is known as the guide strand (or miRNA). The other strand, called the
passenger (or miRNA*), is released and typically degraded [24]. In some instances,
either one of the strands can become the guide or both can be used [21].
Not all miRNAs are generated through this canonical pathway of microRNA biogenesis.
Some miRNAs are not dependent on Drosha, such as mirtrons, which are cut into
pre-miRNA by the spliceosome, a molecular complex responsible for removing introns
(and sometimes exons) from precursor mRNA [89]. The biogenesis of miR-451 is
independent of Dicer; miR-451, which has an important role in erythropoiesis, is
cleaved by Ago2 [14].
3.4 MicroRNA mechanism of action
RISC is the effector of RNA interference, and Ago functions as its catalytic engine.
MicroRNA sequence guides the RISC to target messenger RNAs [35]. Figure 3
illustrates a rough outline of how miRNAs act to regulate mRNA expression.
Target recognition is based on sequence complementarity of the miRNA and mRNA.
In animal miRNAs this complementarity is almost always limited [3]. Nucleotides at
positions 2-8 of the 5’ end of the microRNA have been found crucial to target mRNA
matching; these nucleotides are termed the miRNA "seed sequence". miRNA target
sequences are mostly located in the 3’ UTR (untranslated region) of the mRNA
transcript, but in some instances target sites also reside in the coding region or 5’
UTR of the mRNA [8].
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Figure 3: Depiction of the canonical (and mirtron) pathway of microRNA biogenesis and
microRNA mechanism of action. miRNA biogenesis begins in the nucleus, where the pri-
miRNA is transcribed, then cut by Drosha to the pre-miRNA and exported into the cytoplasm
by Exportin 5 (XPO5). Mirtrons do not require Drosha processing. The pre-miRNA is then
bound by Dicer, which (aided by TRBP) cuts and unwinds the miRNA into its mature form.
RISC is then formed and, guided by the miRNA, regulates gene expression by translational
repression or degradation of mRNA. See text for more details. Black arrows depict the
movement of miRNA molecules through the process, and gray arrows the action of RISC on
the target mRNA. ORF: open reading frame (the protein-coding section) of mRNA. Figure
reprinted with permission from Melo and Esteller [73].
MicroRNAs act through inhibition of mRNA translation or destabilization and
subsequent degradation of mRNA. The exact mechanisms by which the miRNA
and Ago induce translational repression or destabilization of mRNA are unclear [35].
Translational inhibition was earlier believed to be the major form of miRNA action
in animals, but recent evidence suggests that mRNA destabilization predominates
[44]. Rarely, the mRNA can be directly cleaved by Ago [24].
mRNAs bound to RISC accumulate in so called processing bodies (P-bodies), which
are known sites of mRNA catabolism and translational repression in the cytoplasm.
The localization in P-bodies, however, appears to be a consequence of RNA silencing,
not the cause, and is reversible [32].
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Interestingly, several alternative mechanisms of action for microRNA have been
reported, illustrating the complexity and diversity of microRNA biology and gene
regulation. For example, some miRNAs can increase the translation of target mRNA
instead of repressing it [109], miR-373 was found to target DNA promoter areas
and act to induce gene transcription [86], and miR-328 targets a protein to prevent
inhibition of mRNA translation [29].
3.5 MicroRNA function
MicroRNAs assert extensive control over the transcriptome, and have been found to
participate in regulation of almost all studied cellular processes, including embryo
development, cell proliferation and differentiation, apoptosis, and metabolism. More
than 60% of human mRNA transcripts are predicted to be regulated by miRNAs
and most have target sites for several different miRNAs [36]. Furthermore, a single
microRNA can have as many as hundreds or thousands of target mRNAs.
The effect of a single miRNA on the expression of its target tends to be subtle [6].
Thus, microRNAs are considered fine-tuners of gene expression. However, the modest
effect can be enhanced by multiple binding sites and multiple miRNAs acting on the
same target, enabling synergistic interactions [8].
It should be noted, however, that the functional role and importance of many miRNA-
mRNA interactions are unknown, even for validated interaction pairs. Uncovering
these roles is challenging due to the subtle regulatory effects miRNAs have and,
additionally, because of the complexity and robustness of many cellular regulatory
networks [8]. Furthermore, experimentally validated targets have been recognized for
only a fraction of all known microRNAs. Nonetheless, discovering miRNA targets is
a critical step in understanding their function.
3.6 Quantification of microRNA expression
The same methods that are employed for quantifying mRNA expression are generally
also applicable to measuring microRNA expression, and the three principal methods
used are qPCR, microarrays and next-generation sequencing [50]. However, as Hunt
and colleagues in a recent review point out, there are several challenges in detecting
miRNA expression in particular [51].
MicroRNAs are very short and typically comprise approximately 0.01% of RNA
typically extracted from any tissue sample. This implies that miRNA detection
methods must be highly sensitive. Additionally, microRNAs from the same family
can differ by only one base, which in turn requires high specificity to distinguish
between members of the same miRNA family. On the other hand, variation in
miRNA processing can result in slight sequence variations, or isoforms, of a single
miRNA, also known as isomiRs [64]. This means high specificity or an incorrect
reference sequence (e.g. that of a weakly-expressed isomiR) used for detection can
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cause inaccurate measurements. IsomiRs may also have different functions resulting
from altered target specificity [18].
These issues mean that miRNA expression data measured with microarrays are often
quite noisy. Proper filtering and normalization techniques are, therefore, necessary
in analyses of such data. A review of different miRNA microarray platforms and
preprocessing methods has been written by Sah et al [91].
Many of these methodological limitations are resolved by next-generation sequencing
(NGS) approaches, which are sensitive and reliable in quantifying known miRNAs
and enables identification of novel ones [50]. Sequencing can detect variations of
single nucleotides and does not depend on previously identified sequences. However,
not all identified short RNAs are functional miRNAs, and NGS conveys its own set
of problems relating to significant computational complexity and validation efforts
to distinguish relevant data from noise [51].
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4 Cancer
Cancer is a disease of uncontrolled overgrowth of a population of cells. It is generally
viewed as a genetic disease, albeit it is mostly not inherited, as it is caused by
mutations in the genome of the tumor. These mutations cause malfunction and
dysregulation of the genetic machinery regulating cellular functions, such as cell
proliferation, differentiation and apoptosis, resulting in unregulated growth and
malignant tumor formation.
There are several classes of genes that influence tumor growth, the two main categories
being oncogenes and tumor suppressors. Oncogenes, first identified in retroviruses,
promote tumor growth by overexpressing their gene product, leading to for example
abnormal cell-cycle control and increased cell division. [108]. Tumor-suppressor genes
are often regulators of cell proliferation and inactivation of these genes can lead to
tumor progression. The existence of tumor suppressors was first hypothesized by
Alfred Knudson [58]. Knudson also formed the “two-hit hypothesis”, which suggests
that, for cancer to develop, both copies of a tumor suppressor gene should become
inactivated and that in inherited cancers one mutation is acquired in the germ-line
and the other occurs in somatic cells.
The Hallmarks of Cancer are a set of six features which tumors often acquire to
become malignant The hallmarks were suggested Douglas Hanahan and Robert
Weinberg [46] in their seminal article in 2000, and consist of sustaining proliferative
signaling, evading growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and metastasis. Hanahan
and Weinberg postulated that at least three of these six features are required for
invasive cancer to develop.
Recently, Hanahan and Weinberg [47] revised the Hallmarks with two new hall-
marks and two enabling characteristics. The new hallmarks are deregulation of
cellular energetics and avoiding immune destruction. The enabling characteristics
of malignant tumors are genome instability and mutation, and tumor-promoting
inflammation through recruitment of the immune system. Genome instability and
mutation are decidedly important features, as much of cancer research focuses on
identifying mutated or dysregulated genes that promote tumor progression.
4.1 Breast cancer
Breast cancer constitutes a significant health issue globally. It is the most common
cancer in women and the second most common cancer overall; approximately 1.7
million women develop breast cancer annually world-wide, and in 2012 there were
522,000 breast cancer-related deaths [34]. In Finland there were 5,008 new breast
cancer cases and 815 breast cancer-related deaths in 2014 [98].
Most breast cancers are sporadic; only 5-7% of breast cancer cases are of familial type
[72]. However, 15-30% of breast cancer patients have a family member or relative
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with breast cancer. This is mostly due to the high frequency of breast cancer in many
western populations, but also suggests that there are unknown genetic factors and
environmental factors that have an impact on breast cancer development. Indeed,
breast cancer is a hormone-related disease and hormonal factors, most importantly
estrogens, are known to have an impact on breast cancer development.
The most common hereditary forms of breast cancer are related to mutations in the
breast cancer genes BRCA1 and BRCA2, which explain about 25% familial breast
cancer in many populations. These, however are rare on the population level and
familial clustering of beast cancer is multifactorial and caused by moderate risk and
low risk genetic variations, which are much more common [72].
4.1.1 Breast cancer classification
Breast cancers are heterogeneous in their nature and classified by morphology (the
microscopic structure of cancer tissue). The morphological classification of breast
cancer is based on the WHO classification from 2003 and includes altogether 19
histological subtypes of invasive breast cancer [99, 114]. Of these, invasive ductal
carcinoma is by far the most common. Additionally, the WHO classification of breast
cancer includes the TNM classification (consisting of the size of the primary tumor
(T), whether the tumor has spread to lymph nodes (N) or metastasized (M) into
other tissues), and grading into well, moderately or poorly differentiated tumors
based on microscopical examination, with less differentiated tumors having worse
prognosis [99].
In the clinic several other tumor characteristics, such as patient age, and the expression
of estrogen (ER) and progesterone receptors (PR) and Her2, are used to group
patients into prognostic categories. Treatment regimens can be chosen using for
example the St Gallen criteria [39], which classifies tumors into highly endocrine
responsive, incompletely endocrine responsive, and endocrine non-responsive based on
the expression of estrogen and progesterone receptors in tumor cells and, consequently,
the response to endocrine treatment.
One of the problems with morphological classification is that over 50% of tumors do not
show any particular features, although tumors in this large group have highly variable
outcomes. Additionally, endocrine-responsive tumors can become non-responsive as
tumor cells accumulate genomic mutations [78]. Therefore, personalized molecular
diagnostics are required to tailor targeted treatments.
More recently, expression profiling has led to a suggestion of new classification of
breast cancers. Studying the expression profiles of breast tumors, Perou et al [83]
distinguished four subgroups based on gene expression, namely ER+/luminal-like,
basal-like, Erb-B2+ and normal breast, The subgroups were shown to correlate
with prognosis and a 50-gene test (PAM50) was devised to classify tumors into the
subtypes [80].
Other prognostic tests based on expression signatures, including Oncotype DX (a
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21-gene recurrence score) and MammaPrint (a 70-gene test), have also been proposed
to help to determine the need of adjuvant chemotherapy. These tests have been
suggested to be valid and promising, but their utility in clinical decision making
remains unclear [5].
4.2 MicroRNAs and cancer
The dysregulation of microRNAs is associated with many human diseases, such
as neurological disorders, diabetes and cancer [53]. A disease-promoting role for
miRNAs has been implicated in many different cancers [73], including breast cancer,
and research has shown microRNAs to have important roles in tumor initiation,
progression and metastasis [68].
MicroRNA expression signatures correlate with numerous cancer features, such
as tissue of origin, progression, prognosis and treatment response, and all studied
cancers have had miRNA expression profiles differing from healthy tissue [12]. In
fact, microRNAs appear to be generally underexpressed in cancers [69]. Therefore,
it seems clear that microRNAs participate in many of the pathways resulting in the
hallmarks of cancer, and examples of miRNAs influencing each of the hallmarks have
been found. Similarly to protein-coding genes, microRNAs can function as tumor
suppressors or oncogenes [68]. For instance, in a meta-analysis of dysregulation of
miRNAs in breast cancer, van Schooneveld et al [106] found five major oncogenic
and nine major tumor suppressive microRNAs.
The genetic mechanisms for microRNA involvement in cancer are varied, including
mutations in miRNA or target mRNA sequence, chromosomal rearrangements of
the miRNA-encoding DNA regions and epigenetic changes in DNA methylation or
histones, leading to aberrant miRNA expression [12, 73]. For example, a single-
nucleotide polymorphism in the microRNA miR-196a2 has been found to be associated
with breast cancer risk [37]. A mutation in the sequence of estrogen receptor alpha,
in the target site of miR-453, has been suggested to be associated with a lower
breast cancer risk [100], an example of a mutation in a target transcript affecting
miRNA function. MicroRNA function can also be altered by abnormalities in the
miRNA-processing machinery. For instance, a mutation in the Dicer gene causes a
tumor predisposition syndrome known as DICER1 syndrome [93]. Another example
of this is apparent dysregulation of Dicer and Drosha in breast cancer [116].
The different subtypes of breast cancer, explained above, reflect the genetic back-
ground of the tumor and, accordingly, the subtypes differ in their gene expression
profiles. This also applies for miRNA expression, the different intrinsic subtypes have
different miRNA expression profiles, suggesting their importance in breast cancer
evolution [11]. de Rinaldis et al [23] identified a 46-miRNA signature that could be
used in differentiating the intrinsic subtypes from each other. In addition to tumor
development, many miRNAs have been found to modulate the response to breast
cancer therapies. These include chemotherapy, antiendocrine therapy, radiotherapy
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and targeted therapies.
Accordingly, miRNAs have been studied as biomarkers for diagnosing cancer and
cancer prognosis. Emmadi et al [30] recently found let-7 expression to be negatively
correlated with the Oncotype DX recurrence score in breast cancer. This corroborated
with the earlier finding of let-7 being downregulated in breast cancer stem cells (tumor
cells possessing the ability of self-renewal) [117] and later research suggesting let-7
to act as a tumor suppressor. Several miRNAs have also been associated with breast
cancer metastasis [15].
MicroRNAs also show promise as a novel therapeutic tool. Several studies have
tested miRNA-based cancer treatments in animal models with encouraging results
[105]. However, more research in this area is needed before microRNA treatments
are ready for the clinical setting.
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5 Computational identification of miRNA targets
Recognizing the targets of microRNAs is essential in understanding their biological
function and role in disease. Many target interactions have been found in experimental
laboratory studies. Common methods for such studies include using cell lines and
introducing exogenous miRNAs by transfection or suppressing endogenous ones
and measuring the effect on mRNA or protein expression. For a detailed review of
experimental methods, see Thomson et al [101].
Several public databases list currently known experimentally validated microRNA
targets. Examples include DIANA-TarBase [111] and mirTarBase [17], which are
both manually curated from published literature, and MiRWalk [27], which combines
data from several other databases using text mining.
Although recent advances in high-throughput methodologies, such as CLIP-seq, have
significantly increased the scale of experimental studies, experimental identification
of microRNA targets remains laborious and costly, and many methods still rely on
computational processing of results [111]. To this end, a wide range of computational
tools have been developed to aid in miRNA target discovery.
Computational approaches to target prediction can be roughly classified into solely
sequence-based tools and tools based on analysis of expression data (which often
incorporate sequence-based predictions). This section presents an overview of pub-
lished methods developed for target prediction. Examples of these methods are
shown in Table 2. For more in-depth reviews, see references [77, 118].
5.1 Sequence-based target prediction
Sequence-based prediction methods focus on finding miRNA-mRNA pairs that have
complementary sequences, as sequence complementarity is the primary determinant
of miRNA targeting. From a machine learning perspective, prediction of miRNA
targets is essentially a classification problem, where the goal is to identify a set
features (both of the miRNA and mRNA) that allows classifying mRNAs as either a
target or a non-target of any given miRNA.
Most sequence-based approaches are essentially rule-based filters, where features of
both the miRNA and mRNA sequence are used to narrow down candidate target lists
[118]. These features are derived from earlier experimental knowledge, and commonly
used features include: (i) sequence matches between the seed region of the miRNA
and 3’ UTR of the mRNA, (ii) sequence matches outside the seed region (in the 3’
UTR), (iii) sequence matches in the 5’ UTR or coding sequence of the mRNA, (iv)
free energy of the bound miRNA-mRNA duplex, and (v) evolutionary conservation
of matches between species. Rule-based prediction methods are unsupervised, i.e.
no training data is used to form the classifier. Instead, the relevance of the used
features is decided by the method’s authors. An example of a rule-based algorithm
is depicted in Figure 4.
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Table 2: Examples of tools for computational prediction of miRNA targets. All listed methods,
except MAGIA, account only of suppression by miRNAs.
Method: type of inference method used for predictions.
SVM: support vector machine. HMM: hidden Markov model. MI: mutual information.
Seq. used: sequence features considered (sequence-based methods) or use of previous
sequence-based predictions (expression-based methods); see text for more details.
i: sequence matches between the seed region and 3’ UTR, ii: sequence matches outside the
seed region (in the 3’ UTR), iii: sequence matches in the 5’ UTR or coding sequence of the
mRNA, iv: free energy of the bound miRNA-mRNA duplex, v: evolutionary conservation of
matches between species.
prefilter: sequence-based predictions used as a filter prior to analysis.
prior: sequence-based predictions included in prior distributions
Name Method Seq. used Additional notes
Sequence-based methods
TargetScan [1] rule based i,ii,iv,v Originally the first published target
prediction tool.
miRanda [10] rule based i,ii,v Aligns whole miRNA to mRNA 3’
UTR.
mirTarget [113] SVM i,ii,iii,iv,v
rna22 [74] Markov chain and
rule
i,ii,iv Uses a Markov chain to identify
potential regions in mRNA 3’ UTR
and then sequence-rule filtering.
PicTar [60] rule and HMM (i, iv,v) Semi-supervised-like approach;
uses strict sequence rulesi,iv,v to
obtain a training set for a HMM
classifier.
TargetBoost [90] genetic
programming
learned Learns sequence features and clas-
sifier from training data.
Expression-based methods
MAGIA [92] correlation, MI prefilter Also produces a bipartite network
of miRNA-mRNA interactions.
TaLasso [76] lasso regression prefilter
Engelmann et al [31] least angle regression none/prefilter Least-angle regression is a specific
implementation of lasso.
miRNAmRNA [104] global test prefilter Uses mRNA expression profiles to
predict miRNA expression.
GenMir++/3 [48, 49] Bayesian regression prefilter/i,iv,v GenMir3 can incorporate sequence
features into the model.
Stingo et al [96] Bayesian variable
selection
prior Effectively a spike-and-slab variable
selection approach, scores from
any sequence-based method can be
used as prior information.
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Figure 4: A schematic of the miRanda [10] algorithm for miRNA target prediction. The
algorithm takes as input a set of miRNA and mRNA sequences. It then searches the mRNA
3’UTRs for the seed sequence of each miRNA and performs an alignment of the miRNA
and mRNA if the seed is found. Then thee free energy of the aligned miRNA-mRNA
duplex is computed, and finally a conservation score between several species is computed
for the aligned section of the mRNA. At each step a score threshold is used for filtering
miRNA-mRNA pairs to the final set of candidate pairs. Modified with permission from [55].
Supervised machine-learning approaches has also been employed, where a training
data set consisting of experimentally validated targets and non-targets (often obtained
from expression data sets) is used to train a classifier for classifying mRNAs as miRNA
targets. Support vector machines (SVM) are the most common choice for classifier.
The features used for classification are similar to rule-based tools, i.e. mostly derived
from sequences, but supervised learning allows the inclusion of much more features.
For example mirTarget uses a set of 113 features including seed region matches,
conservation and a range of different sequence features from different parts of the
miRNA sequence [113]. More complex approaches have also been applied, such as
using genetic programming to learn sequence features, and using Markov chains or
hidden Markov models (HMM) as a sequence generative model to estimate targeting
probability.
The advantage of sequence-based methods is that they are based on experimentally
derived knowledge on molecular mechanisms and, thus, are likely to represent causal
relationships. As such, the predictions are easy to interpret. Disadvantages of
sequence-based methods include: considering only pair-wise interactions cannot
capture combinatorial effects; using sequence conservation misses poorly conserved
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species-specific targets; requiring seed region matches cannot identify miRNA targets
without seed matches (while these appear rare, they should not be discounted
altogether [8]); a sequence match does not always confer repression and could be
functionally inactive; and, finally, rule-based methods are static and do not account
for differing miRNA and mRNA expression profiles in various tissues and disease
states. There is also a general lack of overlap between predictions from different
sequence-based approaches, suggesting that many results are spurious false positives
[77].
5.2 Expression-data-based target prediction
Integrating expression data with sequence-based target prediction helps combat the
high false-positive rate of sequence-only methods and, importantly, enables tissue
and disease specific support for target predictions in real-world data. Recent evidence
indicates that miRNAs act predominantly through mRNA degradation [44]. Thus,
it is feasible to use mRNA or protein expression data to infer target relationships,
since the regulatory effect of miRNAs should be reflected in mRNA and protein
abundances. Sequence-based predictions are often incorporated as a preliminary
filter step to limit the potential interactions examined.
Various mathematical approaches, ranging from correlation to complex Bayesian
models, have been proposed for expression-based prediction. Most methods limit
the studied relationship to repression by the miRNA. This has been suggested to
improve performance [76], but has the limitation of not being able to detect positive
regulation, both direct and indirect (mediated through regulation of other mRNAs)
[31]. Notably, the majority of published efforts use either protein or mRNA expression
together with miRNA expression, very few have combined all three.
Let us henceforth define yk = [y1k, . . . ynK ] as a vector of expression values of mRNA
k(k = 1, 2, . . . , K) and Xn×p = [xj] = [xij] as the matrix of expression values of
miRNAs j(j = 1, 2, . . . , p) for observations i(i = 1, . . . , n).
Correlation Several methods and publications use a straightforward approach
to identifying miRNA targets by finding miRNA-mRNA pairs whose expression
patterns are similar across observations. This is achieved with simple measures of
variable association. Pearson correlation is widely used because of its simplicity
and intuitive interpretation. Pearson correlation between mRNA k and miRNA j is
defined as:
ρkj = (yk)Tµk=0|σk=1 · (xj)µj=0|σj=1, (1)
where µ = 0|σ = 1 indicates normalization to zero mean and unit variance. Signifi-
cantly correlated miRNA-mRNA pairs are classified as putative target interactions.
Other measures used include Spearman correlation and mutual information (MI).
A crucial limitation of correlation analysis is being restricted to studying pair-wise
associations. Single miRNAs often have a small effect on mRNA expression, which
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leads to weak associations and, therefore, low power to identify miRNA targets. This
issue is worsened by a large multiple-hypothesis testing problem when considering all
possible miRNA-mRNA pairs. Some approaches have used additional information,
such as sequence-based prediction or differential expression analysis, for limiting
examined miRNA-mRNA pairs to alleviate this to some extent [77].
Multivariate linear regression Many proposed expression-based methods use
some form of multivariate linear regression (MLR) to examine the relationship
between miRNAs and mRNAs. Expression profiles of miRNAs are commonly used
to predict the expression of a single mRNA. Recently, Engelmann and Spang [31]
reported that miRNA expression can indeed be used to predict mRNA expression.
In the context of regression, target prediction essentially becomes a variable selection
problem, where the goal is to choose a set of miRNAs that best predict mRNA
expression without overfitting.
A linear regression model for the expression of mRNA k is defined as
yk =
p∑
j=0
(βkj · xj) + k = Xβk + k, (2)
where βk = [βk0, . . . , βkp] is the vector of regression coefficients, βk0 is the intercept
term, k is the error term, and X is the matrix of covariates, i.e. the miRNA
expression vectors (where a constant column vector of x0 = 1 has been added for the
intercept). The parameter of interest is βk, which determines to the contribution
of each miRNA to the response variable yk, i.e. mRNA expression. The regression
error k represents noise and fitting error caused by variation not captured by the
included covariates. k is commonly assumed to be normally distributed, with equal
variance and no correlation between observations, giving the normal linear model. It
is straightforward to incorporate previous sequence-based predictions by adding an
indicator variable yk = Xckβk + k, where ckj = 1 if mRNA k is a potential target of
miRNA j, and ckj = 0 otherwise.
The advantage of using regression for target prediction is the ability to model the
effect of several miRNAs on one gene simultaneously. Simple MLR is not applicable
in cases, where the number covariates is larger than the number of observations (here
p > n) 2, because the linear model is undetermined and a single solution cannot be
obtained. Furthermore, simple MLR cannot solve the problem of variable selection
as the model fit improves asymptotically by adding more covariates, leading to
overfitting.
Regularized regression Both the dimensionality problem and overfitting can be
overcome using regularized regression. The most common approach is to apply regu-
larized least squares, where a penalty depending on the magnitude of the coefficients
2A characteristic that is very common in analysis of high-throughput biological data, for example
microarray expression data.
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β is applied to force them small. This entails minimizing the expression
min{‖yk −Xβk‖2 + λR(βk)}, (3)
where the first term corresponds to fitting error (the sum of squared residuals), R(βk)
is the penalty function and λ is a tuning parameter that controls the amount of
regularization. The 1-norm (R(βk) = ‖βk‖1 =
∑j
j=0 |βkj|) is frequently used for
regularization; this is referred to as lasso regression (shorthand for least absolute
shrinkage and selection operator). Lasso regression in effect forces the number of non-
zero coefficients in βk to be small, leading to a sparse solution that chooses seemingly
important covariates. While regularization solves the dimensionality problem and
improves interpretability, it has several important limitations. Firstly, regularization
may remove covariates highly associated with and functionally regulating the response,
instead retaining an unimportant covariate that correlates with actual regulators
[31]. Secondly, only a limited number of covariates may be included in the model,
and thus some relevant associations can be missed by number of included covariates
alone. Relating to both limitations, van Iterson et al [104] showed that lasso did not
consistently select highly correlated miRNA-mRNA pairs.
Other approaches Other suggested approaches used include the global test [104],
which is a generalization for testing the global null hypothesis (H0 : β = 0) of
a linear regression model when p >> n, and approaches similar to gene-set en-
richment analysis, where the over-representation of sequence-based target genes in
differentially-expressed gene sets is considered indicative of a target relationship
in the studied condition. Le at al [62] have proposed an ensemble method, which
combines predictions from several separate algorithms to build on the advantages
and compensate for the drawbacks of each. Several Bayesian approaches have also
been proposed; these are discussed in the next section.
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6 Bayesian analysis
Bayesian data analysis is a modeling framework that is based on the principle of
quantifying uncertainty as probability. Current knowledge about unknown model
parameters, variables and future observations is described in terms of probability
statements [38]. This provides a framework which is inherently suited to dealing with
noisy real-world data, as measurement noise is naturally incorporated into probability
distributions. This section provides a brief introduction into Bayesian analysis and
discusses Bayesian regression and variable selection as applicable to the problem of
microRNA target prediction.
6.1 Basics of Bayesian analysis
Bayesian analysis begins by defining a joint probability model p(y, θ) for observed
data y and unknown model parameters θ. The joint distribution can be written as a
product of two probability distributions
p(y, θ) = p(θ)p(y | θ), (4)
which are referred to as the prior distribution p(θ) and the data distribution or
likelihood p(y | θ). The prior conveys information on the presumed values a parameter
may take and the likelihood represents the likeliness of observed data for given
parameter values (in the context of the chosen data model). Applying the Bayes’
theorem we obtain the posterior distribution for θ given the known values of the
observations y:
p(θ | y) = p(y, θ)
p(y) =
p(θ)p(y | θ)
p(y) , (5)
where p(y) =
∫
θ p(θ) · p(y | θ)dθ. Noting that p(y) does not depend on θ, we can
write Equation (5) as
p(θ | y) ∝ p(θ)p(y | θ). (6)
The latter is referred to as the unnormalized posterior distribution. The Bayes’
theorem forms the heart of Bayesian inference and illustrates the core concept of
updating prior beliefs to account for observed evidence. The posterior provides
a probability assessment of the possible values of a parameter, and represents a
compromise between prior knowledge and information obtained from observations.
As the number of observations increases, the data have increasing influence on the
posterior [38].
Hierarchical models – where parameters of prior distributions have their own priors,
called hyperpriors – allow significant flexibility in Bayesian modeling. In situations
where model parameters are related to each other, a common hyperprior may be used
for several parameters. Hierarchical models are particularly appropriate in settings
where data are sparse (as available information is shared between parameters) or the
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data are naturally structured into several levels, such as similar measurements from
different hospitals or schools.
The virtue of modeling uncertainty as probabilities – in addition to naturally dealing
with noise – is that they are conceptually easy to grasp and often allow common-
sense interpretations of conclusions to be made.3 Perhaps the foremost advantage
of Bayesian modeling, however, is its flexibility and extensibility; it can cope with
complex problems and data with relative ease. Prior knowledge about the parameters
of interest can be embedded in prior distributions, priors can be assigned freely to
each parameter, hierarchical models can be used to model layered data, and new
observations can be added sequentially to update previous conclusions.
The challenge in Bayesian analysis is choosing proper probability models for the
parameters and observations, including prior distributions as well as the likelihood
[38]. In fact, Bayesian methodology has been criticized for the subjectivity related
to choosing suitable priors. One could, however, argue that the choice of any
model is always subjective to a certain degree, irrespective of chosen methodology.
Additionally, weakly informative or non-informative priors can be used to decrease
the effect of subjective information (or in cases where no prior knowledge is available)
and conclusions from inferences using non-informative priors often coincide with
classical analyses.
6.2 Bayesian inference
The goal of Bayesian inference is to make conclusions about unknown parameters
θ or unknown observations y˜, given the observed data y. These are formulated as
posterior distributions or features describing them, such as point or interval estimates.
In simple cases, the posterior p(θ | y) can be derived in analytical form. In practice,
however, it is often not possible to obtain explicit forms of posteriors or analytical
solutions to integrals involved in inference, especially with complex and hierarchical
models. Therefore, numerical estimation or simulation methods, in the form of
sampling from probability distributions, are frequently used to approximate the
posterior.
The simplest approaches to simulation include sampling directly from the posterior
distribution p(θ | y), when possible, or from a simpler distribution proportional to
p(θ | y) using e.g. rejection sampling [38]. More sophisticated methods are often
needed when dealing with complex models. Markov chain Monte Carlo (MCMC)
is a general approach to simulation that is based on drawing samples of θ from an
approximating distribution. The draws are corrected at each iteration so that the
approximating distribution becomes closer to p(θ | y). Each draw θ(t) is conditional
3This is especially true compared to classical frequentist inference, which is defined within the
context of repeated sampling (and inference) from a fixed but unknown process generating the
observations. For example, frequentist confidence intervals strictly do not indicate that the true
value of the parameter is contained within with high probability – a common misconception – where
as Bayesian posterior intervals do (subject to modeling assumptions).
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(only) on θ(t−1), the previous draw .4 MCMC methods are applicable to arbitrary
posterior distributions and a range of programs for running simulations of full Bayesian
inferences are available.
A key issue with iterative methods, such as MCMC, is running the simulation long
enough, so that the distribution for drawing samples has converged close enough to
the target distribution. Basic solutions to this include discarding a burn-in period
of samples from the beginning of each simulation (to assure that the samples arise
from a converged state), and running several separate simulations (chains) with
different starting points to improve coverage of the posterior. Various approaches to
measuring convergence have been proposed.
6.3 Bayesian regression
Bayesian regression analysis aims to infer the posterior distributions for the regression
coefficients of covariates and other model parameters, such as the variance (i.e. the
error term) of the observation model. Within the Bayesian framework, the normal
linear regression defined in Eq. (2) can be expressed as
y | β, σ,X ∼ N(Xβ, σ2I), (7)
where N is the multivariate normal distribution, and I is the n× n identity matrix
(the gene index k has been suppressed for clarity). The mean of y is then the familiar
linear sum of xk
E(y | β,X) = Xβ = β0 + β1x1 + · · ·+ βpxp. (8)
The posterior distribution for the regression coefficients (up to a normalizing constant)
is obtained from the marginal posterior
p(β | σ, y,X) ∝
∫
p(y | β, σ,X)p(β | σ)p(σ)dσ, (9)
with the joint prior p(β, σ) = p(β | σ)p(σ). It is relatively straightforward to extend
this simple model, for instance by allowing unequal variances or correlation between
observations, choosing a different data distribution to represent the error term, or
including hyperparameters to construct a hierarchical model.
As mentioned in Section 5.2, microRNA target prediction using regression analysis
of expression data is effectively a variable selection problem. For Bayesian regression,
several different priors that provide model shrinkage have been proposed, including
the Laplace prior (which is closely related to lasso regression), the horseshoe prior,
and the hierarchical shrinkage prior (a generalization of the horseshoe). A hierarchical
shrinkage prior for regression weight βj can be formulates as
βj | λj, τ ∼ N(0, λ2jτ 2)
λj ∼ t+ν (0, 1),
(10)
4This is essentially the definition of a Markov chain; a sequence of random variables, where the
probability density of each one is dependent on only the previous one.
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where t+ν denotes the half-Student-t prior with ν degrees of freedom [84]. The λj
correspond to a local scale parameter and τ controls the amount of global shrinkage.
As an example, in a very sparse model with many irrelevant covariates, the model
would ideally have small τ (so that p(β) is mostly shrunk close to zero), but allow
some λj to be large to escape the shrinkage.
A weakly informative half-Cauchy distribution is often the suggested choice of prior
for τ , but van der Pas et al have also proposed (for the horseshoe prior) using a fixed
value of τ = pn
n
√
log(n/pn), where pn is the assumed number of relevant covariates
and n is the number of observations [103]. Bayesian shrinkage priors, however, do not
lead to a sparse solution as there remains uncertainty in the posterior distribution
and no coefficient can be considered exactly zero.
6.4 Bayesian variable selection
In order to find a small set of relevant predictive variables, a model selection approach
needs to be applied. To this end, a range of methods applicable in Bayesian
analysis have been proposed; examples include using cross validation, different
information criteria, and projection methods to determine the submodel giving the
best compromise between prediction accuracy and model size. A detailed review of
these falls outside the scope of this thesis, however, a comprehensive one has been
recently written by Vehtari and Ojanen [110].
In the context of variable selection for regression, Piironen and Vehtari [85] recently
suggested that, for problems where data are scarce and the number of candidate
variables high, using projection predictive variable selection is effective. The idea,
proposed by Dupuis and Robert [25], is to fit a full reference modelMref encompassing
all candidate variables, and then project the information in the reference posterior
onto a submodel M⊥ so that the predictions are as similar as possible.
Given the reference model parameters θr, the projection θ⊥ in the parameter space
of M⊥ is obtained by solving
θ⊥ = argmin
θ
1
n
n∑
i
KL (p(y˜ | xi, θr,Mref) ‖ p(y˜ | xi, θ,M⊥)) , (11)
where KL (P ‖ Q) is the Kullback-Leibler divergence between probability distribu-
tions P and Q. The discrepancy between the reference model Mref and submodel
M⊥ is then defined as the expectation of the divergence over the posterior of the
reference model:
δ(Mref ‖M⊥) = 1
n
n∑
i
Eθr|D,Mref [KL (p(y˜ | xi, θr,Mref) ‖ p(y˜ | xi, θ⊥,M⊥))] . (12)
The posterior expectation in (12) can, in practice, be estimated by drawing samples
from the reference posterior (using e.g. MCMC). It can be shown, that in the case of
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normal linear regression, the minimization in (11) can be solved analytically and the
discrepancy (12) has a simple form depending only on the reference and projected
model variances σ2 [84].
A practical issue with this method is deciding how many variables should be included
in the submodel. This depends on what is considered acceptable loss of prediction
performance compared to the submodel. Piironen and Vehtari suggest using cross-
validation to guide the variable selection process and give a practical guideline for
stopping the selection. This is discussed Section 7.2.5. In this thesis, projection
predictive variable selection was used for inferring putative microRNA targets from
breast cancer expression data using Bayesian regression. Further details of the used
method are presented in Section 7.2.5.
6.5 Bayesian microRNA target-prediction methods
One of the earliest tools to use expression data for target prediction was GenMir++
[48]. It takes as input a candidate set of miRNA targets (the authors have used
TargetScanS) and uses mRNA and miRNA expression data across multiple tissues to
predict whether a given candidate miRNA-target interaction is real. GenMir is based
on a Bayesian regression model, where mRNAs are assumed to share a tissue-specific
common background expression, which is downregulated by regulating miRNAs. Let
µt represent the background mRNA expression in tissue t, the probability model for
mRNA expression ykt is defined in GenMir as:
ykt | X,Sk,Γ,Λ, µt,Σ ∼ N
µt − γt p∑
j
λjskjxk,Σ
 , (13)
where γt is a tissue-specific scaling factor (modeling differences in mRNA and miRNA
measurements and normalization) and λj are regulatory weights of the miRNAs
(irrespective of candidate target k), and skj an indicator variable of target interaction.
Compared to Eq. (7), the degree of regulation of a miRNA becomes βkj = γtλjskj.
The goal is to infer the posterior p(skj | ckj = 1, D,M), that is, the probability
of a candidate interaction being true, where ckj is an indicator variable of the
input putative interactions. A log-odds score is given for each miRNA-mRNA
interaction.
The latest version of GenMir (GenMir3) defines Gamma priors for γt and λt and
Bernoulli priors for skj (leading to negative interactions only) and allows including
sequence features in a logit hyperprior for the prior p(skj). The model is solved
simultaneously for all genes and tissues, using a variational Bayes method, to obtain
an approximate posterior for S. The authors note, that the method can be easily
extended to add protein expression.
Another Bayesian approach to target prediction is a Bayesian network method
published by Stingo et al [96]. The approach is essentially an implementation of the
spike-and-slab variable selection method [110] applied to a Bayesian regression model
28
equivalent to Eq. (7). Sequence features are included in the (Bernoulli) prior of the
covariate inclusion variable S. The posterior for S is obtained with MCMC methods.
A time-dependent coefficients version is also presented for data measured for several
time points. Additionally, many published analyses of different expression data for
target prediction have utilized various probabilistic or Bayesian approaches.
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7 Materials and methods
7.1 Research material
Analyses performed in this thesis used protein, mRNA and microRNA expression
data previously published by Aure et al [4]. The miRNA and mRNA data are publicly
available on the Gene Expression Omnibus [28] (accessions GSE8210 and GSE8212,
respectively) and the protein data is provided as supplementary data in [4].
The data consist of 283 tumor samples collected from 280 breast cancer patients
treated in two Norwegian hospitals. The data are part of the larger Oslo2 cohort,
which consists of breast cancer patients with primarily operable disease [4]. Collection
of the cohort started in 2006 and is still ongoing. Therefore, no survival data were
available for analysis. Patient ages ranged from 30 to 83 years with a median of 55
years. The vast majority of tumors in the data were ductal carcinomas, which is the
most common type of breast cancer, however, in general the dataset consisted of a
heterogeneous collection of different histological types and stages of breast cancer
tumors. No matched control samples of healthy breast tissue were available.
The mRNA and microRNA expression were measured using Agilent Technologies
(Santa Clara, CA, USA) SurePrint G3 Human GE 8x60K and Human miRNA
Microarray Kit (V2) microarrays, respectively. These microarrays measure 27958
genes and 887 miRNAs, according to manufacturer annotation. Protein expression
was measured with reverse-phase protein arrays (RPPA) [102] for a selected set of
105 proteins relevant in cancer. Most of the proteins are found on the PI3K/AKT
intracellular pathway, which plays a central role in cell-cycle regulation.
7.2 Methods
A Bayesian regression model of protein, mRNA and miRNA expression data was con-
structed, and projection predictive variable selection was used to predict microRNA
targets in breast cancer data. Details of the methods used are presented in this
section.
All computational analyses were performed in R [87] and workflow management
was handled with Anduril [79]. Monte-Carlo simulations for the Bayesian regression
models were computed with RStan [95] using the No-U-Turn variant of a Hamiltonian
Monte Carlo algorithm for sampling posterior distributions. The simulations were
performed using computer resources within the Aalto University School of Science
"Science-IT" project.
30
7.2.1 Preprocessing and quality control
The preprocessed miRNA and mRNA data5 were downloaded from GEO using
the GEOquery [22] R package. The protein data were downloaded and extracted
from a Microsoft Excel file. All of the data had been transformed to log2 scale,
which is useful for making the distribution of expression values closer to a normal
distribution.6 No further preprocessing of the expression values was done. For details
on the preprocessing process, the reader is referred to the supplementary data of
Aure et al [4]. In regression analyses, all variables (miRNA, mRNA and protein) were
further scaled to have zero mean and unit variance; this transformation is commonly
used for regression.
The mRNA expression data were available as probe-level measurements, these were
summarized to gene-level using manufacturer probe annotations by taking the mean
of all probes targeting the same gene. Out of 421 miRNAs present in the data, eleven
had been deleted from miRBase. These miRNAs (namely hsa-miR-1274a, hsa-miR-
1274b, hsa-miR-1280, hsa-miR-1308, hsa- miR-1826, hsa-miR-1974, hsa-miR-1975,
hsa-miR-1977, hsa-miR-1979, hsa-miR-720, hsa-miR-886-3p) were therefore from all
analyses.
Members of the AKT and GSK gene families (namely AKT1, AKT2, AKT3 and
GSK3A, GSK3B) were not distinguishable in the protein assay. Therefore, the
protein data included only a single set of measurements for each family. For the
analyses presented here, each of these genes was considered separately using the
same expression values for all family members.
For assessing the quality of the data, distributions of expression values for each tumor
sample and each variable (miRNA, mRNA and protein) were visualized using boxplots.
A principal component analysis (PCA) and hierarchical clustering of samples were
performed separately for each data type to assess possible bias introduced by the
data having been measured at two separate hospitals.
7.2.2 Validated target reference
The predicted miRNA targets obtained in the analyses were compared to validated
targets in DIANA-TarBase v7.0 [111] (referred to as TarBase from here on) and
miRTarBase release 6.0 [17]. Data from both databases were downloaded and a union
of the databases was used as a reference set of validated interactions. The resulting
set contained 328825 validated miRNA-mRNA interactions, out of which only 4082
were between a gene and miRNA present in the analyzed data, however.
5Raw array data produced from Agilent array readers are also available, but were not used in
this thesis.
6Raw expression values are approximately log-normal.
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7.2.3 Correlation analysis
To assess dependencies between variables from the different expression data types
(protein, mRNA, miRNA) and the validity of correlation as a target prediction tool,
Pearson’s correlations were computed between matched and unmatched protein-
mRNA pairs (where matched refers to both corresponding to the same gene) as well
as validated and random protein-miRNA and mRNA-miRNA pairs, where validated
pairs were ones present in the reference set described above. The random correlations
consisted of 5000 randomly picked pairs (with replacement).
7.2.4 Regression models
For predicting protein expression from mRNA and miRNA expression, a similar
regression model to Aure et al was used:
y = β0 + zβg +Xβ + , (14)
where y is the protein expression and z the mRNA expression for gene k (k is
suppressed for clarity), wg is the regression coefficient for the mRNA, X is the matrix
of miRNA expression vectors, and w0 is the intercept term (for a justification of this
equation, see [4]). A separate model was fitted for each gene. A model with only the
mRNA expression covariate (called the gene-only model), defined as y = β0 + zβg + ,
was used as a baseline. A normally distributed error term with equal errors and no
correlation between observations was assumed for all models.
The likelihood for Bayesian regression was therefore defined as
y|β, σ, z,X ∼ N(β0 + zβg +Xβ, σ2I), (15)
where β = [β0, βg, β] for convenience. The intercept and mRNA coefficient were given
diffuse Gaussian priors and σ a uniform prior:
β0 ∼ N(0, 52) (16a)
βg ∼ N(0, 52) (16b)
σ ∝ 1. (16c)
A hierarchical shrinkage prior was applied to the miRNA coefficients β, as defined in
Equation (10). The degrees of freedom for the λj priors was set at ν = 3 (similar to
Piironen and Vehtari [84]). The prior for τ was defined as:
τ ∼ half-Cauchy
(
0, pn
n
√
log(n/pn)
)
, (17)
combining the previous suggestions of half-Cauchy and fixed tau. The assumed
number of relevant miRNAs, pn, was estimated as follows. Ensembl (release 86)
gene ID’s were downloaded for all protein-coding genes in the human genome using
biomaRt [26]. From these, a sample of 1000 genes was taken, and known validated
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microRNA interaction partners for each sampled gene were downloaded from miRWalk
[27]. Genes for which there were no validated miRNA interactors were assumed
to have zero. The mean number of miRNA interactors per gene was used as the
estimate, giving pˆn = 13.75.7
7.2.5 Variable selection
Projection predictive variable selection (as described in Section 6.4 and as applied
by Piironen and Vehtari [84]), was used to obtain the relevant set of microRNAs
for each gene. A full reference model was fitted by drawing 2000 samples from the
posterior using RStan (with 4 chains, 1000 samples each and the first half discarded
as burn-in). A random sample of S = 1000 simulation samples from the full posterior
was used to increase projection speed.
A series of projected submodels was obtained using a forward search strategy, that is,
the search started from a model including only the intercept, the mRNA expression
z was always added as the first covariate, and at each subsequent step, the miRNA
covariate xj giving the largest decrease in discrepancy between the reference and
projected models (Eq. (12)) was chosen. The forward search was continued up to
200 variables.
For choosing the model size, 10-fold cross validation was used, as proposed by Piironen
and Vehtari [85]. This means that the above model selection process was repeated
K = 10 times, each time leaving out n/K observations for model evaluation. For
judging the appropriate model size, estimation of model predictive performance was
performed as explained below.
Model predictive performance The predictive performance of each submodel
was evaluated using a log predictive density. Given submodel M⊥ with the posterior
predictive distribution p(y˜|z˜, X˜⊥, β⊥, σ⊥, D⊥), where D⊥ is the observed data in
the current submodel and cross-validation fold and (β⊥, σ⊥) the projected model
parameters, the logarithm of the predictive density (LPD) was computed at each of
the left-out observations (y∗, z∗, X∗). The LPD was estimated by averaging over the
S simulated posterior samples:
LPD∗(M⊥) ≈ log 1
S
S∑
s
p(y∗|z∗, X∗, β⊥, σ⊥, D⊥).
The LPD values from each cross-validation fold were pooled and their mean over
the full set of data (MLPD) was used as a summary. To compare the predictive
performance of a submodel to the full reference model, the difference in MLPD
(∆MLPD) was computed. Bayesian bootstrap [88] (with 5000 samples) was used to
7Note that this is probably an underestimate of the true pn, as the set of experimentally validated
miRNA targets is very likely to underrepresent the true in vivo set of miRNA targets.
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estimate a distribution for ∆MLPD as:
∆MLPDb(M⊥,Mref) =
n∑
i
w
(b)
i [LPDi(M⊥)− LPDi(Mref)] ,
where w(b)i , i = 1, . . . , n, are the bootstrap weights for the b’th bootstrap sample
(subject to ∑iw(b)i = 1). The bayesboot R package was used for computing the
bootstrap. The ∆MLPD(M⊥,Mref) was then used as an estimate of the predictive
performance of submodel M⊥.
Choosing model size For choosing the model size, the following condition was
used:
Pr(∆MLPD(M⊥,Mref) > U) ≥ α, (18)
where U = γ∆MLPD(M0,Mref), and M0 refers to the intercept-only model. The
number of covariates in the smallest model satisfying this condition was chosen as the
final model size. This means that model size was chosen such, that the probability
of the projected model improving performance by a constant factor (γ) over the
intercept-only model was at least α. The choice of values for γ and α reflects accepted
loss in predictive performance (and related uncertainty) compared to the reference
model; several values for both were tested.
Final model selection The final projected model was obtained by reapplying the
projection search up to the chosen number of variables, using all data for each gene.
miRNAs included in each gene’s model were considered putative target interactors.
miRNAs for which the 95% posterior interval did not include the origo were considered
significant. For some genes the condition in (18) was not met after including 200
covariates. In these cases it was concluded that the miRNA covariates provided
no additional information on the protein expression and, thus, none of them were
deemed as targeting the gene. In some cases the condition was met already by the
model with only the mRNA covariate, and the same conclusion was made.
Lasso regression A lasso regression model was also fitted for each gene using the
glmnet R package. In this case the mRNA variable was treated equal to the miRNA
variables and subjected to the lasso regularization. For choosing the regularization
parameter λ, the default algorithm of glmnet was used. That is, models were fit for
a decreasing sequence of λ values, and 10-fold cross validation was used to compute
a mean square prediction error (MSE) at each λ. The largest value of λ (i.e. sparsest
model) that had a MSE within one standard error of the lowest MSE attained in the
cross validation was used. The covariates included in the model using the chosen λ
were considered putative target interactors. For some genes, this criterion was met
by the intercept-only model, and again, in these cases none of the miRNAs were
deemed as targeting the gene.
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7.2.6 Measuring model fit
To assess convergence of simulations, the potential scale reduction measure Rˆ proposed
by Gelman et al was used [38]. The coefficient of determination R2 was used as a
measure of regression model performance. R2 is defined as
R2 = SSresiduals
SStotal
=
∑n
i=1(yˆi − yi)2∑n
i=1(yi − y¯)2
, (19)
where yˆi are the predictions made by the model and y¯ is the mean of the outcome
variable y. R2 corresponds to the proportion of variance of the outcome variable that
is explained by a statistical model, and can be used as a measure of model fit. R2
has the property of being invariant to variable scaling, which makes it suitable for
use with expression data, as expression data do not have a well defined scale.
An important caveat of R2 is that in linear regression it often increases monotonically
by adding more explanatory variables. The adjusted R2, defined as R¯2 = 1− (1−
R2)n−1
n−p (where n is the number of observations and p the number of explanatory
variables) adjusts for the number of regressors relative to the number of observations,
thus penalizing inclusion of additional variables. Therefore, R¯2 was used for comparing
the projected model with the gene only model.
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8 Results
Quality control
The protein and mRNA expression data appeared reasonably uniform and mRNA
data were approximately normally distributed, but several protein variables had
long tails and a few had significant outliers. 28 of the protein variables had values
that were further than 5 standard deviations away from the mean (highly unlikely
assuming normal distribution) and proteins CDK1, ERRFI1, and PIK3CA had one
value over 8 standard deviations away from the mean. These are visually most
apparent in the scaled data shown in Figure .
miRNA microarrays had strongly bimodal distributions with a gap between the
modes, many miRNA variables were highly skewed towards very small expression
values, and there appeared to be some quantification artifacts in the miRNA data
(see Figures C6 and C7). This raises suspicion of significant noise in the miRNA data,
actual miRNA abundances should not have such a clear gap in their distribution,
and values below the gap possibly corresponded to miRNAs not actually expressed
in the data. miRNA variables that had bimodal distributions could signify that these
miRNAs are not expressed in some of the breast tumor types in the data.
No significant hospital batch effect was apparent in the data. The samples collected
at the different hospitals did not cluster into separate groups in principal component
analysis (shown in Figure C1) or hierarchical clustering (not shown) of any of the
three data types. All quality control plots are available in Appendix C.
Correlation analysis
Correlation between protein and mRNA expression was low on average. Protein-
mRNA correlation was clearly higher for gene-matched pairs (that is protein and
mRNA expression corresponding to the same gene) than unmatched pairs, however,
even the gene-matched correlations were quite low, with mean ρ¯ ≈ 0.37. Using the
squared correlation coefficient ρ2 as a measure of explained variance, the amount
of protein variance explained by the matched mRNA ranged from 0% to 82% with
a mean of 21%. Distributions of Pearson correlation for matched and unmatched
protein-mRNA pairs are shown in Figure .
Correlations between miRNAs and their validated target genes were not significantly
different from random gene-miRNA pairs (data shown in Figure ). The validated
target pairs showed no preference towards negative (or positive) correlation. There
was virtually no difference in correlations between validated targets and randomly
picked gene-miRNA pairs, contrary to what might be expected. These finding were
replicated when comparing miRNA and protein data (Figure ).
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Figure 5: Distributions of Pearson correlations between variables of different expression data
types. The distributions are trimmed at the smallest and largest values. (a) Correlation
between protein and mRNA pairs, where "matched" refers to correlating protein and mRNA
from the same gene. Matched pairs tended to have higher correlations, but the correlations
were low, nonetheless. (b) Correlation between protein and miRNA pairs, where "validated"
refers to the gene being a validated target of the miRNA (according to TarBase), and
"random" to a randomly picked group of protein-miRNA pairs. (c) Correlation between
mRNA and miRNA pairs, where grouping is the same as in (b). There was no difference
between validated target pairs and random pairs in (b) and (c).
Model simulations
Simulations for the cross validation (to determine model size) lasted between 4
to 6 hours (on a computing-cluster node with 2 12-core Xeon E5 2680 2.50GHz
processors), and simulations for the final projected models lasted between 2 to 45
minutes, depending on the chosen model size. All parameters for all simulations had
low potential scale reduction Rˆ2 < 1.1, indicating good convergence of simulation
chains [38].
The parameters for the model-size criterion, α and γ, had a significant effect on the
resulting model sizes and the number of models found. Model-size distributions for
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several parameter values are shown in Appendix B. Values α = 0.50 and γ = 0.2
were chosen in order to get a projected model for most genes and to keep models
relatively sparse. This choice was, however, largely subjective.
A projected model was found for 74 genes out of the 105 genes in the data. For
the rest, no miRNA variables were included in the model for 27 genes, and the
model-size criterion was met in under 200 variables for 4 genes. Figure 6 shows the
predictive performance during the forward search in cross validation for one of the
best performing models (CDH3 ) and one for which no model was found (PIK3CA).
A table of properties for the final projected models is available in Appendix A.
Figure 6: Predictive performance (∆MLPD) of projected submodel M⊥ during each step of
the forward search in the model-size-selection phase. Two of the 105 models are shown.
The black curve shows the median (corresponding to α = 0.50) and gray lines the 95%
interval of ∆MLPD computed with Bayesian bootstrap. The red line depicts the model-size
selection threshold U (with γ = 0.2). The model size was chosen as the point where the
black curve crosses the red line. The final CDH3 model (shown left) was one of the best
performing ones, no model was found for PIK3CA (shown right), as the intercept-only model
already performed better than the full model.
Projected models larger than approximately 28 miRNA variables performed increas-
ingly poorly as the model size increased. This is illustrated in Figure 7. A similar
trend was observed by trying different model-size threshold parameters α and γ (data
not shown).
Lasso regression produced models with at least one miRNA for 74 genes, out of which
only 57 were common to the ones found by projection prediction (PPVS). For 18
of the lasso models, the mRNA expression variable was excluded from the chosen
model. Figure 8 shows a comparison of model size distribution and ∆R¯2 between
PPVS and lasso.
Target prediction performance
Considering each selected miRNA variable as a putative miRNA-mRNA target
interaction, PPVS generated a total 945 target predictions, out of which 253 were
significant (on a 95% posterior interval). Table A1 lists the significant predictions.
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Figure 7: Size of final model compared to model goodness-of-fit. The x-axis corresponds to the
total number of chosen miRNA variables in each final projected model (N miRNAs). The
three y-axes show the number of significant miRNA variables (N significant miRNAs), R2 of
the projected model (R2full), and the difference in R¯2 between the projected and gene-only
models (∆R¯2). Higher values for the y-axes are better. Each point represents one model
fitted for one gene. A small jitter has been added to the points on the x-axis to help visualize
all of them. Curves were fitted with locally weighted scatter plot smoothing (LOESS) and
shaded areas represent 95% confidence interval. A trend can be seen, where models larger
than approximately 28 included miRNAs perform increasingly poorly.
Lasso regression generated all together 650 target predictions. Figure 9 shows the
overlap of predictions by PPVS and lasso, and also that of significant predictions from
PPVS and the same number of top predictions from lasso, where lasso predictions
were ranked by the absolute value of the regression coefficient.8
PPVS regression coefficients for miRNA covariates had larger magnitude (i.e. absolute
value) on average than lasso, for target interactions predicted by both, implying
stronger miRNA effects on protein expression. Correlation of the coefficients was
fairly high (0.86), and there were only three predicted targets for which the methods
did not agree on the sign of the coefficient. A scatter plot comparing the coefficients
of the common predictions is shown in Figure 10.
8Lasso regression does not provide any rank measures or tests of significance.
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Figure 8: Comparison of final model sizes (shown left) and increase in proportion of protein
variance explained compared to the gene-only model (∆R¯2, shown right) between projection
prediction (PPVS) and lasso regression. PPVS models were slightly smaller on average
(though the difference was not significant). The predictive performance of PPVS was better
(as measured with ∆R¯2).
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Figure 9: Venn diagrams showing the overlap of all target predictions from PPVS and lasso
(shown left) and the overlap of significant (on the 95% posterior) predictions from PPVS
and the same number of top predictions from lasso (ranked by absolute value of regression
coefficient). There is very little overlap between the predictions made by the two methods.
The proportion of overlap is slightly larger for the significant and top predictions.
PPVS and lasso had similar performance in regards of discovering validated targets;
limiting predictions to the ones with most confidence did not significantly increase the
proportion of validated targets for either method. Approximately 12% of PPVS and
14% of lasso predictions were present in the union of TarBase and miRTarBase. These
proportions were 13% and 14% for the significant PPVS and top lasso predictions,
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Figure 10: Comparison of miRNA regression coefficients from projection prediction (PPVS,
x-axis, posterior median) and lasso regression (y-axis) for the 145 targets predicted by both
methods. Triangles are significant coefficients in PPVS. The gray line (y = x) corresponds to
equal coefficients from the two methods. The coefficients from PPVS had larger magnitude
on average, implying stronger miRNA effects on protein expression. cor: Pearson correlation
between the coefficients.
respectively.
For both methods, approximately half of the coefficients for both all predicted and
validated targets were positive, indicating upregulation by the miRNA. In contrast,
in TarBase, all of the discovered validated interactions were classified as suppressive.
miRTarBase does not provide data on the nature of the regulation.
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9 Discussion
This thesis presents a review of the basics of gene expression, microRNAs and the
computational prediction of microRNA target genes. A modern Bayesian variable
selection method was applied in the context of regression, to predict protein expression
from mRNA and miRNA expression in breast cancer tumor samples, with the goal
of identifying putative miRNA target. The Bayesian method was compared to lasso
regression, a popular method for target prediction from expression data.
Quality control plots suggested the presence of noise in the data, especially in the
miRNA microarrays. More strict filtering of miRNA data could lead to better overall
results. The choice of data model can also alleviate the effects of noise. The student-t
distribution, which has heavier tails than the normal distribution, would likely be
a better choice for the regression model likelihood. This, however, would require a
different solution to the projection Eq. (11) than the one derived by Piironen and
Vehtari [84] and, therefore, was not tried in this work.
Correlation between mRNA and protein measurements for the same gene were
mostly low, a finding supported by previous studies [82]. Interestingly, there was
practically no difference between correlations of validated miRNA-target pairs or
randomly chosen ones. This supports the view that modeling single interaction pairs
individually is unlikely to be sufficient for effective target prediction using expression
data.
It is possible that low correlation of miRNA-target pairs was mostly due to the
dataset used and measurement noise it contained, however, correlation has low power
to detect weak relationships and cannot capitalize on combinatorial effects. The
low correlations also suggest that simple (Pearson) correlation of expression data
is possibly inadequate for finding miRNA targets. Poor prediction results using
correlation have been reported before (see for example [76]).
There could be several explanations for the increasingly poor performance of larger
models, evident in Figure 7. The largest models could be a result of the covariates not
explaining the outcome variable well. This results in a large model, as the inclusion
of each covariate can provide only a minute improvement to submodel performance
and, therefore, a large number of covariates is required to satisfy the criterion for
choosing model size. The assumption that the reference model represents the best
current knowledge could also be false, as seemed to be the case for some genes where
the submodels performed consistently better than the full model. This likely means
that the reference model has overfit the training data (in the cross- validation).
From a biological perspective, poor performance means that the microRNAs did not
provide additional information for predicting protein expression after accounting for
gene expression. This could be due to relevant miRNAs missing from the dataset, the
number of observations being too small leading to low statistical power (unable to
capture the often small effect that miRNAs have), or the biological heterogeneity of
breast cancer. The proposed regression model could also be inadequate for capturing
42
the actual biological effect of miRNAs, though previous research seems to suggest
otherwise.
Compared to lasso regression PPVS achieved better model fit, yet from a target
prediction perspective, performance of the two methods was similar. There was
little overlap of predictions made by the two methods, a common issue in microRNA
target prediction [104]. Only a small fraction of predicted targets were validated
according to TarBase and miRTarBase, however, this is probably true of all miRNA
targets in general; only a limited number of validation studies have been published.
The computational cost of PPVS was significantly higher than that of lasso: MCMC
simulations took hours compared to less than a minute per model for lasso.
Approximately half of the regression coefficients for miRNAs were positive, suggesting
that those miRNAs increase gene expression. Some of these could indicate indirect
regulation. However, this proportion seems too high, as the vast majority of known
microRNA interactions are suppressive. In fact, of all the experimentally validated
human miRNA targets listed in TarBase, only approximately 0.2% show positive
regulation by the miRNA. Therefore, many of the predicted activating interactions
are possibly false findings. They could be caused by miRNA expression mirroring
the involvement of other regulatory factors not included in the data. To correct
for this, the model could easily be restricted to only negative interactions (using a
non-positive prior for β). This has previously been reported to increase prediction
performance [77].
Previous studies have shown that microRNA signatures correlate with different breast
cancer subtypes [11]. This suggests that using pooled datasets of various tumors,
such as the data used in this study, is likely to miss subtype-specific miRNA effects,
unless this is accounted for in the model. This could be achieved in the proposed
method by constructing a hierarchical model that includes tumor-subtype data.
Another way to improve the proposed model would be to include sequence-based
target information, as most published methods do. This could be achieved with
indicator variables, a weighting scheme, or more elaborately by including sequence-
based data within the hierarchical-shrinkage prior to impose less regularization on
putative target pairs. However, as the authors of GenMir noted, including sequence
features did not result in a significant improvement of their method [49].9
The proposed model does not account for the fact that microRNAs have several,
even hundreds, of target transcripts [36]. Therefore, the regulatory effect of a single
miRNA is most likely spread across several genes. In combination with transcripts
having several regulating miRNAs, this many-to-many nature of microRNA regulation
ultimately calls for computational methods that model the whole regulatory network
at once, such as regression models with multivariate targets. This, however, becomes
a much more difficult problem than multivariate linear regression.
9It should be noted, that GenMir uses sequence-based predictions as a preliminary filter step.
Therefore, it is perhaps not surprising that including the same type of data within the model does
not produce substantial improvement.
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Aure et al [4] used lasso regression for a similar analysis of the same dataset. They
used a multi-step process, where only miRNAs deemed significant in a univariate
regression model were used as input in multivariate lasso regression. This approach
is flawed in the sense, that it loses some of the power of multivariate models to
identify singly weak but combinatorially strong effects, as univariate modeling is
used as a filtering step. It also effectively uses the same data twice, causing bias, and
introduces a multiple hypothesis testing problem. Therefore, a multivariate approach
(such as the one presented here or earlier ones with slight modification) would likely
be preferable.
In conclusion, the work in this thesis shows that the proposed method of projection
predictive variable selection is applicable to microRNA target prediction. However,
further refinements to the model are warranted to improve performance. In the
presented form, compared to a simpler alternative, the method offered only a limited
advantage from a modeling perspective, and no apparent advantage from a biological
perspective, but incurred a large computational burden. The choice of parameters α
and γ, which define the threshold for model size, proved nontrivial. The values chosen
had a large impact on the sizes of resulting models and, therefore, a data-driven
approach for optimizing the parameter values would perhaps be useful.
Future prospects
The recent development of CLIP-seq and similar methods has made high-throughput
experimental microRNA target discovery possible, partially replacing the need
for computational target prediction. Nonetheless, experimental (particularly high-
throughput) methods are not immune to error, and gene regulation is vastly complex
with many unconventional regulatory mechanisms having been discovered. Inte-
grative computational approaches beyond correlation – combining several types of
data – will, thus, remain important in the future. Possibilities for integrating data
include incorporating copy number variation, other regulatory RNAs, transcription
factors, other protein-level regulatory factors such as phosphorylation, and epigenetic
mechanisms into models.
The elucidation of complex regulatory networks using network-level modeling is
becoming feasible with modern experimental and computational methods. Employing
this approach will be essential, as it has the ability to better capture the true nature
of gene regulation and cellular biology.
Many aspects of microRNA biology and function still remain unknown. Uncovering
miRNA function offers interesting possibilities in diagnostics and treatment of disease,
and will further our understanding of the complexities of molecular cell biology.
Therefore, microRNAs remain an exciting avenue of research.
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A Table of model properties
Table A1: Properties of fitted models for all 105 genes. A missing value for N miRNAs
indicates a projected model was not found (i.e. the stopping criterion was not satisfied
before reaching 200 covariates), a zero indicates no miRNA variables were chosen. R2 was
not computed for models with no miRNA variables. Only the significant miRNAs chosen are
listed for compactness of display.
R2gene: R2 for gene-only model
R2⊥: R2 for projected model obtained with PPVS
∆R¯2: Difference of adjusted R2 of projected model versus gene-only model
∗: gene expression variable is significant (95% credible interval)
NmiRNA: number of miRNA variables in projected model (number of significant miRNA
variables, 95% credible interval)
Gene R2gene R2⊥ ∆R¯2 NmiRNA Significant miRNAs
ACACA 0.462∗ 0.524∗ 0.062 2 (2) miR-30a, miR-370
AKT1 0.111∗ 0.174∗ 0.064 2 (2) miR-449a, miR-342-5p
AKT2 0.001 0.230 0.195 14 (4) miR-342-5p, miR-449a, miR-96, miR-146b-5p
AKT3 0.000 0.251 0.216 15 (4) miR-342-5p, miR-449a, miR-96, miR-146b-5p
ANXA1 0.380∗ 0.425∗ 0.047 1 (1) miR-765
AR 0.713∗ 0
BAK1 0.119∗ 0.228∗ 0.110 2 (2) miR-29c, miR-505*
BAX 0.130∗ 0.405∗ 0.228 23 (4) miR-557, miR-659, miR-142-3p, miR-199a-3p
BCL2 0.728∗ 0
BCL2L1 0.088∗ 0.354∗ 0.123 53 (1) miR-622
BCL2L11 0.176∗ 0.318∗ 0.143 2 (2) miR-29c, miR-34a
BECN1 0.005
BID 0.015∗ 0.134 0.122 1 (1) miR-1246
BIRC2 0.018∗ 0.243∗ 0.226 2 (2) miR-1246, miR-425
BRAF 0.094∗ 0.456∗ 0.352 8 (8) miR-638, miR-125b, miR-1321, miR-107,
miR-765, miR-148a, miR-135b, miR-505*
CASP8 0.014 0.111∗ 0.091 4 (4) miR-99a, miR-148a, miR-631, miR-126*
CAV1 0.284∗ 0.432∗ 0.147 3 (3) miR-551b, miR-24
CCNB1 0.638∗ 0.714∗ 0.076 2 (2) miR-199a-5p, miR-30a
CCND1 0.334∗ 0.497∗ 0.153 8 (7) miR-936, miR-181c, miR-622, miR-493*,
miR-19a, miR-126, miR-9*
CCNE1 0.544∗ 0
CDH1 0.449∗ 0
CDH2 0.006 0
CDH3 0.165∗ 0.584∗ 0.398 17 (13) miR-155, miR-10b*, miR-502-5p, miR-224,
miR-489, miR-148a, miR-195, miR-197,
miR-361-5p, miR-650, miR-150, miR-501-5p,
miR-582-5p
CDK1 0.037∗
CDKN1B 0.418∗ 0.491∗ 0.075 1 (1) miR-195
CHEK1 0.019∗ 0.168 0.122 11 (0)
CHEK2 0.512∗ 0
CLDN7 0.234∗ 0.363∗ 0.125 4 (4) miR-29c, miR-200c, miR-30b, miR-150
COL6A1 0.000 0.325 0.321 4 (4) miR-125b, miR-638, miR-210, miR-24
CTNNA1 0.081∗ 0.113∗ 0.033 2 (1) miR-125a-3p
CTNNB1 0.002 0.339 0.287 22 (5) miR-711, miR-10a, miR-31*, miR-16,
miR-28-5p
Continued on next page. . .
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Gene R2gene R2⊥ ∆R¯2 NmiRNA Significant miRNAs
DIABLO 0.089∗ 0.483∗ 0.336 31 (6) miR-378, miR-339-3p, miR-762, miR-15b,
miR-144*, miR-582-5p
DVL3 0.068∗ 0.377∗ 0.283 14 (9) miR-24, miR-498, miR-140-3p, miR-223,
miR-29c, miR-21, miR-432, miR-662, miR-204
EEF2 0.009 0.330 0.292 14 (3) miR-106b, miR-196b, miR-29c*
EEF2K 0.310∗ 0
EGFR 0.148∗ 0.356∗ 0.189 10 (7) miR-181d, miR-181b, miR-1182, miR-495,
miR-30c, miR-126, miR-183*
EIF4E 0.100∗ 0.252∗ 0.050 36 (0)
EIF4EBP1 0.495∗ 0
ERBB2 0.729∗ 0
ERBB3 0.204∗ 0.334∗ 0.128 3 (3) miR-199a-5p, miR-451, miR-484
ERCC1 0.004 0
ERRFI1 0.012
ESR1 0.825∗ 0
FN1 0.495∗ 0
FOXO3 0.094∗ 0.225∗ 0.128 3 (3) miR-140-3p, miR-631, miR-197
GAB2 0.597∗ 0
GATA3 0.708∗ 0
GSK3A 0.106∗ 0.473∗ 0.319 26 (5) miR-21, miR-29a, miR-20a, miR-100, miR-92a
GSK3B 0.064∗ 0.524∗ 0.275 81 (0)
IGF1R 0.637∗ 0
IGFBP2 0.553∗ 0
INPP4B 0.754∗ 0
IRS1 0.397∗ 0.441∗ 0.046 1 (1) miR-93
KDR 0.000 0.281 0.272 6 (6) miR-150, miR-663, miR-495, miR-24-1*,
miR-363, miR-140-3p
KIT 0.581∗ 0
KRAS 0.037∗ 0.335 0.264 16 (2) miR-96, miR-21
MAP2K1 0.006 0.141 0.138 1 (1) miR-21
MAPK14 0.017∗ 0.346∗ 0.301 14 (9) miR-145, miR-92a, miR-181c, miR-142-3p,
miR-425, miR-339-3p, miR-342-5p, miR-18b,
miR-1226*
MAPK9 0.193∗ 0.251∗ 0.061 1 (1) miR-342-5p
MAPT 0.020∗ 0.335 0.270 20 (3) miR-30c, miR-132, miR-17*
MET 0.031∗ 0.085∗ 0.054 2 (2) miR-125b, miR-139-5p
MRE11A 0.012 0.290 0.052 70 (0)
MSH2 0.333∗ 0
MSH6 0.340∗ 0.628∗ 0.265 19 (10) miR-125b, miR-324-5p, miR-25, miR-195*,
miR-451, miR-154, miR-551b, miR-26b,
miR-513a-5p
MYC 0.025∗ 0.101∗ 0.076 2 (2) miR-150*, miR-24
NCOA3 0.132∗ 0
NF2 0.132∗ 0.321∗ 0.187 3 (3) miR-638, miR-125b, miR-22
NOTCH1 0.216∗ 0.279∗ 0.064 2 (2) miR-199b-5p, miR-502-5p
NOTCH3 0.150∗ 0.401∗ 0.245 5 (5) miR-125b, miR-27b, miR-193a-5p, miR-32,
miR-139-5p
PARK7 0.288∗ 0.428∗ 0.140 2 (2) miR-93, miR-29c
PCNA 0.229∗ 0.283∗ 0.057 1 (1) miR-199a-5p
PECAM1 0.054∗ 0.169∗ -0.028 43 (0)
PGR 0.819∗ 0
PIK3CA 0.051∗ 0
Continued on next page. . .
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Gene R2gene R2⊥ ∆R¯2 NmiRNA Significant miRNAs
PIK3R1 0.077∗ 0.377∗ 0.295 5 (5) miR-142-3p, miR-342-3p, miR-501-5p,
miR-145*, miR-92a
PRKAA1 0.119∗ 0.240∗ 0.121 2 (2) miR-199a-3p, miR-342-3p
PRKCA 0.368∗ 0
PTCH1 0.029∗ 0.167∗ 0.127 6 (2) miR-145, miR-934
PTEN 0.029∗ 0.468∗ 0.370 35 (5) miR-204, miR-498, miR-324-3p, miR-30d,
miR-22
PTGS2 0.065∗ 0.114∗ 0.052 1 (1) miR-1246
PTK2 0.021∗ 0.273∗ 0.242 6 (5) miR-1246, miR-150, miR-21, miR-200c,
miR-32
PXN 0.133∗ 0.431∗ 0.140 63 (0)
RAB25 0.031∗
RAD50 0.076∗ 0.106∗ 0.033 1 (1) miR-139-5p
RAD51 0.011 0.205 0.195 2 (2) miR-1246, miR-181c
RAF1 0.121∗ 0.446∗ 0.306 12 (9) miR-125b, miR-1260, miR-498, miR-449a,
miR-130a, miR-30b, miR-28-5p, miR-374a,
miR-195*
RB1 0.006 0.233∗ 0.222 4 (4) miR-145, miR-1260, miR-451, miR-195*
RPS6KB1 0.516∗ 0.617∗ 0.102 2 (2) miR-497, miR-106b
SMAD1 0.359∗ 0.417∗ 0.060 1 (1) miR-106b
SMAD3 0.354∗ 0.475∗ 0.112 7 (7) miR-7, miR-451, miR-181d, miR-29b,
miR-365, miR-1225-5p, miR-1299
SMAD4 0.000 0
SNAI1 0.001 0
SRC 0.308∗ 0
STAT5A 0.292∗ 0.438∗ 0.147 2 (2) miR-155, miR-324-5p
STMN1 0.000 0.364 -0.028 109 (0)
SYK 0.227∗ 0.714∗ 0.462 26 (20) miR-125b, miR-155, miR-324-5p, miR-195,
miR-449a, miR-711, miR-762, miR-940,
miR-22, miR-615-3p, miR-663, miR-377*,
miR-598, miR-126, miR-29b, miR-1228*,
miR-144, miR-204, miR-601, miR-30d
TP53 0.017∗ 0.186∗ 0.161 5 (5) miR-301b, miR-29c*, miR-551b, miR-19a,
miR-874
TP53BP1 0.260∗ 0.357∗ 0.099 1 (1) miR-96
TSC2 0.065∗ 0.318∗ 0.225 13 (3) miR-1915, miR-30b, miR-92a
VASP 0.151∗ 0.193∗ 0.045 1 (1) miR-29c*
XIAP 0.089∗ 0.224∗ 0.136 2 (2) miR-638, miR-99a
XRCC1 0.130∗ 0
YAP1 0.164∗ 0.351∗ 0.183 4 (4) miR-106b, miR-486-5p, miR-28-5p, miR-595
YBX1 0.016∗ 0.329∗ 0.314 2 (2) miR-125b, miR-96
YWHAE 0.001 0.145 0.138 4 (4) miR-21, miR-1260, miR-365*, miR-204
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Figure B1: Distributions of chosen model sizes for differrent values of model-size parameters
α and γ. #0 refers to the number of models with no covariates (i.e. not even the mRNA
covariate was chosen) and #NA to the number of models where the model-size criterion
was not met. The parameter values had a large impact on the final model sizes. Strict
values (α close to one and small γ) generated very large models and had the effect of the
size-criterion not being met for many genes (larger #NA).
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C Quality control plots
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Figure C1: Scatter plots of first two principal components for each tumor sample (or microarray)
computed from (a) protein expression, (b) mRNA expression, and (c) miRNA expression data.
The point color corresponds to the hospital where each sample was handled. The samples from
different hospitals were not distinguishable using the principal components, which suggests that
no significant hospital batch effect was present.
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(a) Protein expression by tumor samples
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(b) Protein variables
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
lll
l
l
l
l
l
l
lll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
l
l
l
l
l
l
ll
l
l
l
l
l
−10
−5
0
5
10
Sc
al
ed
 lo
g2
 e
xp
re
ss
io
n
(c) Scaled protein variables (µy = 0, σy = 1)
Figure C2: Distribution of protein expression, grouped by (a) tumor samples, (b) protein variables
(i.e. microarrays), and (c) protein variables (and scaled to zero mean and unit variance). The
fill color in (a) corresponds to the hospital where the sample was collected. It is evident in (c),
that some of the protein variables have significant outliers (especially the two values beyond 10
and −10).
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Figure C3: Density estimates of protein expression data for each tumor sample (a) and each protein
variable (b). The color of the curves has no significance. Distributions were generally uniform,
but long tails for several protein variables are visible in (b), suggesting the presence of significant
outliers and that these variables were not approximated well by a normal ditribution.
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(a) mRNA microarrays
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(b) mRNA variables
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(c) Scaled mRNA variables (µz = 0, σz = 1).
Figure C4: Distribution of mRNA expression, grouped by (a) tumor samples (i.e. microarrays), (b)
mRNA variables, and (c) mRNA variables (and scaled to zero mean and unit variance). The fill
color in (a) corresponds to the hospital where the sample was collected. The distributions were
fairly uniform and only a few significant outliers (further than 5 standard devations from the
mean) were present in the mRNA variables.
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Figure C5: Density estimates of mRNA expression data for each microarray (a) and each mRNA
variable (b). The color of the curves has no significance. The array distributions were uniform
and quite close to normal. Some of the variable distributions had long tails as seen in (b).
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(a) miRNA microarrays
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(c) Scaled miRNA variables (µx = 0, σx = 1)
Figure C6: Distribution of miRNA expression, grouped by (a) tumor samples (i.e. microarrays),
(b) miRNA variables, and (c) miRNA variables (and scaled to µx = 0, σx = 1). Fill in (a)
corresponds to hospital. The miRNA variables in (b) have been sorted by median expression to
highlight that some miRNAs had very low expression. There appeared to be a gap at around
−8 (confirmed in Fig. C7). Measurements below the gap possibly corresponded to miRNAs not
expressed in the samples, and thus, likely consisted mainly of background noise, Real miRNA
abundances should follow a more continuous distribution. There also seemed to be some technical
artifact around the gap, where some miRNA variables had exactly the same expression value.
No biological phenomenon would explain this. The same order is retained in (c). The scaling
did not correct for the highly skewed distributions of the most lowly expressed miRNAs.
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Figure C7: Density estimates of miRNA expression data for each microarray (a) and each miRNA
variable (b). Color of the curves has no significance. Note the bimodal distributions in (a) and
the corresponding break at around −8 and large spread in location in (b). This suggests that
the miRNAs below the gap were present in such low quantities, possibly not expressed at all,
that the measured expression values likely consisted mostly of background noise.
